The company plans to support its research, development, and commercialization operations as well as general working capital needs with the net proceeds from the offering, including the Final Tranche.
The Company paid an eligible finder cash finder’s fees in the amount of $43,460 in connection with the closure of the Final Tranche.
In compliance with relevant securities laws, all securities issued in conjunction with the Offering’s closure, including those issued in the Final Tranche, will be subject to a statutory hold period of four months plus one day from the date of issuance.
According to the United States Securities Act of 1933, as amended, the securities mentioned in this press release have not been registered and will not be registered. As a result, they cannot be offered or sold within the country, to or for the account or benefit of citizens of the country, unless they are registered there or qualify for an appropriate exemption from the country’s registration requirements. This press release does not represent an offer to purchase or sell any securities. Neither does it solicit offers to acquire any securities.
BioNxt Solutions Inc. is a bioscience accelerator that focuses on next-generation drug formulations and delivery systems, diagnostic screening tests, and the production and evaluation of new active pharmaceuticals. These include: rapid, low-cost screening tests for infectious diseases and oral health; standardisation and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications; and precision transdermal and oral dissolvable drug formulations. The company is currently focusing on regulatory approval and the marketing of medical goods for European markets. It has research and development activities in North America and Europe, with an operational concentration in Germany.
Some of the information in this press release can be considered “forward-looking statements”. This release contains forward-looking statements about events and developments that the company anticipates to happen, with the exception of historical factual information. The terms “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or the assertions that certain events or conditions “will”, “would”, “may”, “could”, or “should” occur, are generally, but not always, indicative of forward-looking statements.
This news release contains forward-looking information, such as how the Offering’s proceeds are expected to be used. Even when the company thinks the expectations outlined in these forward-looking statements are supported by reasonable assumptions, these statements do not guarantee future performance, and actual outcomes might differ significantly from those predicted. The actual outcomes may differ considerably from the forward-looking statements due to various factors such as market pricing, regulatory actions, and the availability of capital and financing, as well as general market, business, and economic circumstances.
Investors are advised that while such statements may seem optimistic, they do not guarantee future performance, and actual outcomes or developments may diverge significantly from those anticipated in the claims. The Company’s management’s estimates, assumptions, and opinions on the date the statements are made form the basis of any forward-looking statements. The Company disclaims any need to update these forward-looking statements in the event that management’s estimates, beliefs, or opinions, or other factors, should change, unless obliged by relevant securities laws.